BGR GOVERNMENT AFFAIRS

Lobbying for ALKERMES, INC. · Biopharmaceutical Company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $50,000.00 income · posted Oct 20, 2025

Lobbying activity 1

Health Issues

Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.